Stockscreener 앱 받기
0.00
100.00%
-8.28
시간 외 거래:
8.45
8.45
+
전일 마감가:
$8.28
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$413.12M
수익:
-
순이익/손실:
$-52.07M
주가수익비율:
0.00
EPS:
-0.2077
순현금흐름:
$-44.93M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$9.83
Cybin Inc Stock (CYBN) Company Profile
명칭
Cybin Inc
전화
908 764 8385
주소
100 King Street West, Suite 5600, Toronto
Compare CYBN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
0.00 | 413.12M | 0 | -52.07M | -44.93M | -0.2077 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | TD Cowen | Buy |
| 2026-02-02 | 개시 | Jefferies | Buy |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Cybin Inc 주식(CYBN)의 최신 뉴스
Helus Pharma reports encouraging Phase 2 results for HLP004 anxiety treatment - MSN
Top Cybin (HELP) Competitors 2026 - MarketBeat
Point72 / Cohen disclose 686,669 shares in Cybin (CYBN) - Stock Titan
Sirenia (CYBN) discloses 3,677,966 shares; 7.2% stake including warrants - Stock Titan
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN
Cybin (HELP) Institutional Ownership 2026 $HELP - MarketBeat
Number of shareholders of Cybin Inc. – NASDAQ:HELP - TradingView
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director - The Globe and Mail
Helus Pharma propels therapeutic innovation in mental health and commences trading on Nasdaq - MSN
TradingKey - TradingKey
EDGAR Filing Documents for 0001628280-25-033606 - SEC.gov
symbol__ Stock Quote Price and Forecast - CNN
Cybin Inc. (NASDAQ:HELP) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
HELP Technical Analysis & Stock Price Forecast - Intellectia AI
Cybin (NASDAQ:HELP) Shares Up 2.7%Should You Buy? - MarketBeat
Helus Pharma Partners With TARA Mind to Boost Phase 3 Depression Trial in Veterans After U.S. Executive Order - TipRanks
Helus Pharma (Nasdaq: HELP) partners with TARA Mind to boost veteran trial access - Stock Titan
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - Investing News Network
Cybin Inc. will Change its Name to Helus Pharma - marketscreener.com
Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference - TipRanks
Helus Pharma (CYBN) interim CEO to join Milken Global Conference health innovation panel - Stock Titan
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference - The Manila Times
A Milken health-innovation panel will feature Helus Pharma's interim CEO - Stock Titan
Helus turns to TARA Mind to reach veterans for depression trial - Stock Titan
MSN Money - MSN
Helus Pharma Partners With TARA Mind to Boost Phase 3 Trial Recruitment for Major Depressive Disorder in Veterans - MEXC
Helus Pharma Aligns With U.S. Veteran Mental Health Push in New TARA Mind Partnership - TipRanks
Cybin (CYBN) Helus Pharma joins TARA Mind to boost HLP003 Phase 3 veteran trial - Stock Titan
Cybin to move US stock listing to Nasdaq from NYSE American - MSN
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - Investing News Network
Helus Pharma partners with TARA Mind for trial recruitment - Investing.com
Helus Pharma partners with TARA Mind for trial recruitment By Investing.com - Investing.com UK
HELP | Cybin Inc. Common Stock Insider Trading - Quiver Quantitative
Cybin initiates at-the-market equity program of up to $100 million - MSN
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
Helus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role - MSN
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk? - Yahoo Finance
Cybin Inc (CYBN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.71%
자본화:
|
볼륨(24시간):